ECSP13012905A - Preparación sólida - Google Patents
Preparación sólidaInfo
- Publication number
- ECSP13012905A ECSP13012905A ECSP13012905A ECSP13012905A EC SP13012905 A ECSP13012905 A EC SP13012905A EC SP13012905 A ECSP13012905 A EC SP13012905A EC SP13012905 A ECSP13012905 A EC SP13012905A
- Authority
- EC
- Ecuador
- Prior art keywords
- solid preparation
- active ingredient
- earth metal
- alkaline earth
- metal salt
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000007787 solid Substances 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- -1 alkaline earth metal salt Chemical class 0.000 abstract 2
- 239000000378 calcium silicate Substances 0.000 abstract 2
- 229910052918 calcium silicate Inorganic materials 0.000 abstract 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 abstract 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona una preparación sólida, en donde se suprime la variación en peso, una preparación sólida en donde el ingrediente activo se estabiliza y su método de estabilización. Una preparación sólida con (1) un ingrediente activo, (2) D-manitol y (3) una sal de metal alcalinotérreo seleccionada de aluminometasilicato de magnesio y silicato de calcio. Un método de estabilización del ingrediente activo, que incluye la adición de una sal de metal alcalinotérreo seleccionada de aluminometasilicato de magnesio y silicato de calcio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011082301 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012905A true ECSP13012905A (es) | 2013-11-29 |
Family
ID=46018066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012905 ECSP13012905A (es) | 2011-04-01 | 2013-09-27 | Preparación sólida |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20150157609A1 (es) |
| EP (1) | EP2694039B1 (es) |
| JP (1) | JP6077459B2 (es) |
| KR (1) | KR20140018923A (es) |
| CN (1) | CN103458878B (es) |
| AR (1) | AR085743A1 (es) |
| AU (1) | AU2012233203A1 (es) |
| BR (1) | BR112013022010A2 (es) |
| CA (1) | CA2831548A1 (es) |
| CL (1) | CL2013002579A1 (es) |
| CO (1) | CO6821945A2 (es) |
| CR (1) | CR20130481A (es) |
| DO (1) | DOP2013000217A (es) |
| EA (1) | EA201391447A1 (es) |
| EC (1) | ECSP13012905A (es) |
| ES (1) | ES2607070T3 (es) |
| GE (1) | GEP20156306B (es) |
| IL (1) | IL228357A0 (es) |
| MA (1) | MA35069B1 (es) |
| MX (1) | MX2013010661A (es) |
| PE (1) | PE20141009A1 (es) |
| PH (1) | PH12013502038B1 (es) |
| SG (1) | SG193328A1 (es) |
| TN (1) | TN2013000356A1 (es) |
| TW (1) | TW201244757A (es) |
| UY (1) | UY33996A (es) |
| WO (1) | WO2012133918A1 (es) |
| ZA (1) | ZA201306799B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112206218B (zh) * | 2020-10-24 | 2022-08-23 | 迪沙药业集团有限公司 | 一种甲硝唑维生素b6组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3145146A (en) * | 1961-10-31 | 1964-08-18 | Warner Lambert Pharmaceutical | Modified mannitol for pharmaceutical tablets |
| CA2429133C (en) | 2000-11-17 | 2009-08-18 | Takeda Chemical Industries, Ltd. | Novel imidazole derivatives, production method thereof and use thereof |
| JP2002308760A (ja) * | 2001-04-06 | 2002-10-23 | Taiyo Yakuhin Kogyo Kk | 圧縮成型用組成物及びその利用 |
| WO2004075890A1 (ja) | 2003-02-26 | 2004-09-10 | Takeda Pharmaceutical Company | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法 |
| JP4745616B2 (ja) * | 2003-02-26 | 2011-08-10 | 武田薬品工業株式会社 | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法 |
| WO2004082679A1 (ja) | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| WO2006093353A1 (ja) | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| JP2011082301A (ja) | 2009-10-06 | 2011-04-21 | Sony Corp | 配線基板、その製造方法および電子機器 |
-
2012
- 2012-03-29 CN CN201280015658.9A patent/CN103458878B/zh not_active Expired - Fee Related
- 2012-03-29 UY UY0001033996A patent/UY33996A/es not_active Application Discontinuation
- 2012-03-29 ES ES12717499.3T patent/ES2607070T3/es active Active
- 2012-03-29 WO PCT/JP2012/059276 patent/WO2012133918A1/en not_active Ceased
- 2012-03-29 US US14/009,277 patent/US20150157609A1/en not_active Abandoned
- 2012-03-29 AR ARP120101068A patent/AR085743A1/es unknown
- 2012-03-29 EP EP12717499.3A patent/EP2694039B1/en active Active
- 2012-03-29 PE PE2013002132A patent/PE20141009A1/es not_active Application Discontinuation
- 2012-03-29 CA CA2831548A patent/CA2831548A1/en not_active Abandoned
- 2012-03-29 MA MA36376A patent/MA35069B1/fr unknown
- 2012-03-29 JP JP2013544599A patent/JP6077459B2/ja not_active Expired - Fee Related
- 2012-03-29 TW TW101111020A patent/TW201244757A/zh unknown
- 2012-03-29 KR KR1020137027148A patent/KR20140018923A/ko not_active Withdrawn
- 2012-03-29 MX MX2013010661A patent/MX2013010661A/es not_active Application Discontinuation
- 2012-03-29 PH PH1/2013/502038A patent/PH12013502038B1/en unknown
- 2012-03-29 EA EA201391447A patent/EA201391447A1/ru unknown
- 2012-03-29 AU AU2012233203A patent/AU2012233203A1/en not_active Abandoned
- 2012-03-29 SG SG2013066956A patent/SG193328A1/en unknown
- 2012-03-29 GE GEAP201213270A patent/GEP20156306B/en unknown
- 2012-03-29 BR BR112013022010A patent/BR112013022010A2/pt not_active IP Right Cessation
-
2013
- 2013-08-28 TN TNP2013000356A patent/TN2013000356A1/fr unknown
- 2013-09-09 CL CL2013002579A patent/CL2013002579A1/es unknown
- 2013-09-10 ZA ZA2013/06799A patent/ZA201306799B/en unknown
- 2013-09-11 IL IL228357A patent/IL228357A0/en unknown
- 2013-09-24 CR CR20130481A patent/CR20130481A/es not_active Application Discontinuation
- 2013-09-27 EC ECSP13012905 patent/ECSP13012905A/es unknown
- 2013-09-30 DO DO2013000217A patent/DOP2013000217A/es unknown
- 2013-10-25 CO CO13254239A patent/CO6821945A2/es not_active Application Discontinuation
-
2016
- 2016-08-24 US US15/245,815 patent/US20170202777A1/en not_active Abandoned
-
2018
- 2018-03-20 US US15/926,373 patent/US20190054026A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201291394A1 (ru) | Твердые композиции | |
| EA201692104A1 (ru) | Ингибиторы асс и их применения | |
| CL2015002865A1 (es) | Composiciones de limpieza que contienen una poliéteramina | |
| EA201391602A1 (ru) | Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей | |
| BR112014017749A8 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
| GT201400181A (es) | Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| TR201902602T4 (tr) | Yağ bazlı haşere öldürücü süspansiyon. | |
| IN2015DN03029A (es) | ||
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| MX2015013480A (es) | Composicion farmaceutica para inhibir la respuesta inmune a traves de la induccion de diferenciacion en celulas t reguladoras y la promocion de proliferacion de celulas t reguladoras. | |
| NZ718373A (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor | |
| MX375892B (es) | Composición que comprende sal de glutamato de acilo como tensoactivo principal o tensoactivo principal aniónico | |
| MX356951B (es) | Estabilizacion de fsh. | |
| EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
| CL2016000027A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. | |
| MY167067A (en) | Smoking agent and smoking device | |
| MX2017006709A (es) | Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales. | |
| GT201300041A (es) | Composicion fungicida sinergista | |
| MX2015013535A (es) | Formulacion de l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| UY32075A (es) | Estabilización de preparaciones acuosas de minerales mediante reuterina | |
| CL2014001127A1 (es) | Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos. | |
| TW201613898A (en) | Benzofuran analogue as NS4B inhibitor | |
| BR112012020399A2 (pt) | solução de acrilamida aquosa estável |